Glioma Pipeline Expands as 180+ Pharma Companies Advance Several Novel Therapies, Finds DelveInsight | Aivita Biomedical, Denovo BioPharma, Medicenna Therapeutics, Eli Lilly, Candel Therapeutics

Glioma – Pipeline Insight, 2026

DelveInsight's "Glioma – Pipeline Insight, 2026" report provides comprehensive insights about 180+ companies, including Aivita Biomedical, Inc., Denovo BioPharma, Medicenna Therapeutics, Inc., Eli Lilly and Company, Candel Therapeutics, Mustang Bio, AstraZeneca, Boehringer Ingelheim, Daiichi Sankyo, Nerviano Medical Sciences, and others developing drugs in the Glioma pipeline landscape.

DelveInsight's "Glioma – Pipeline Insight, 2026" report provides comprehensive insights about 180+ companies and 200+ pipeline drugs in the Glioma pipeline landscape. It covers the Glioma pipeline drug profiles, including clinical and nonclinical stage products, along with therapeutics assessment by product type, stage, route of administration, and molecule type. The report further highlights inactive pipeline products in this space.

Explore the latest breakthroughs in the Glioma treatment landscape. Learn more about the evolving Glioma pipeline today @ https://www.delveinsight.com/sample-request/glioma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr

Key Takeaways from the Glioma Pipeline Report

• In March 2026, GT Medical Technologies initiates BRIDGES trial enrollment, testing GammaTile brachytherapy implant post-resection vs. standard radiation in newly diagnosed GBM to improve survival.

• In March 2026, STELLAR trial reports >45% survival increase (35 months median OS) with eflornithine + lomustine vs. lomustine alone in recurrent grade 3 IDH-mutant astrocytoma.

• In February 2026, IN8bio Phase I/II data shows repeated gamma-delta T-cell therapy yields 13-month PFS and >17-month OS in newly diagnosed GBM, doubling standard care benchmarks.

• In January 2026, Multicenter trial demonstrates focused ultrasound blood-brain barrier opening + temozolomide achieves 13.5-month PFS and 31.3-month OS in newly diagnosed GBM.

• In November 2025, ImmunityBio Phase 2 QUILT-3.078 reports median OS not reached in recurrent GBM with chemo-free ANKTIVA + CAR-NK, bevacizumab, and Optune; reverses lymphopenia.

• DelveInsight's Glioma Pipeline Insight report depicts a robust space with 180+ active players working to develop 200+ pipeline therapies for Glioma treatment.

• The leading Glioma companies include Aivita Biomedical, Inc., Denovo BioPharma, Medicenna Therapeutics, Inc., Eli Lilly and Company, Candel Therapeutics, Mustang Bio, AstraZeneca, Boehringer Ingelheim, Daiichi Sankyo, Nerviano Medical Sciences, and others.

• Promising Glioma therapies under development include AV-GBM-1, DB 107, MDNA55, Abemaciclib, NMS-03305293, CAN-3110, MB-101, and others.

• The company with the most advanced Glioma drug candidate is Aivita Biomedical, Inc., with AV-GBM-1 currently in Phase III clinical development.

• The Glioma pipeline covers all clinical phases as well as inactive and discontinued candidates.

Download for updates and the latest revolution in Glioma care @ Glioma Clinical Trials Assessment

Glioma Emerging Drugs Profile

AV-GBM-1: Aivita Biomedical, Inc.

AV-GBM-1 is an innovative immunotherapy developed by Aivita Biomedical, Inc., specifically targeting glioblastoma (GBM), one of the most aggressive forms of brain cancer. This treatment utilizes autologous dendritic cells loaded with autologous tumor neoantigens derived from tumor-initiating cells. The therapy is administered through a series of subcutaneous injections and aims to enhance the immune response against the patient's unique cancer profile. AV-GBM-1 is currently in Phase III of its clinical trial for the treatment of Glioma.

DB 107: Denovo BioPharma

Denovo BioPharma's DB107 is an investigational gene therapy designed to treat high-grade gliomas, including glioblastoma (GBM), a particularly aggressive form of brain cancer. The therapy utilizes a novel biomarker-guided approach, leveraging the Denovo Genomic Marker 7 (DGM7) to identify patients who are likely to benefit from the treatment. DB107 is currently in Phase II of its clinical trial for the treatment of Glioma.

MDNA55: Medicenna Therapeutics, Inc.

MDNA55 is a targeted therapeutic for recurrent glioblastoma multiforme (rGBM), a uniformly fatal form of brain cancer. By using a highly specific IL-4 Superkine as the delivery vehicle for a potent bacterial toxin, MDNA55 has the potential to purge bulk tumors and disrupt their supporting networks, while reactivating the immune system to combat cancer. MDNA55 is a genetic fusion of two molecules: a circularly permuted IL-4 Superkine and the catalytic domain of the Pseudomonas exotoxin A. Because the IL-4 receptor is not found in a healthy brain and the exotoxin is only active inside cancer cell cytoplasm, healthy cells remain unaffected. MDNA55 is currently in Phase II of its clinical trial for the treatment of Glioma.

Abemaciclib: Eli Lilly and Company

Abemaciclib is an antitumor agent and dual inhibitor of cyclin-dependent kinases 4 (CDK4) and 6 (CDK6) involved in the cell cycle and promotion of cancer cell growth. It selectively inhibits CDK4 and CDK6 with low nanomolar potency, inhibits Rb phosphorylation resulting in G1 arrest and inhibition of proliferation, and its activity is specific for Rb-proficient cells. Abemaciclib has been investigated in trials studying the treatment of melanoma, lymphoma, neoplasm, solid tumor, and glioblastoma. It is currently being evaluated in Phase II development to treat patients with Glioblastoma.

NMS-03305293: Nerviano Medical Sciences

NMS-03305293 (NMS-293) is a second-generation PARP inhibitor distinguished by its unique selectivity for PARP1 versus PARP2 enzymes and low DNA trapping activity — features that are potentially linked to lower hematological toxicity and a higher potential for combination with DNA-damaging agents across a wide range of tumors. It also has a superior ability to penetrate the blood-brain barrier, supporting its utilization in CNS tumors and brain metastases. Based on high anti-tumor activity as a single agent in BRCA-mutated preclinical models and demonstrated synergy with chemotherapy, NMS-293 is currently in Phase II clinical development in combination with temozolomide for recurrent glioblastoma.

CAN-3110: Candel Therapeutics

CAN-3110 is a first-in-class, replication-competent herpes simplex virus-1 (HSV-1) oncolytic viral immunotherapy candidate designed with dual activity for oncolysis and immune activation in a single therapeutic. Its activity is conditional on the expression of Nestin in cancer cells. CAN-3110 is being evaluated in a Phase I investigator-sponsored clinical trial in patients with recurrent high-grade glioma (HGG).

MB-101: Mustang Bio

MB-101 is an IL13Rα2-targeted CAR T cell therapy developed by Mustang Bio, aimed at treating recurrent glioblastoma (GBM) and high-grade gliomas. MB-101 is currently in Phase I of its clinical trial for the treatment of Glioma.

For more information on the Glioma Emerging Drugs Profile, download DelveInsight's comprehensive Glioma Pipeline Insight report.

The Glioma Pipeline Report Provides

• Detailed insights about companies developing therapies for Glioma, with aggregate therapies developed by each company.

• Different therapeutic candidates, segmented into early-stage, mid-stage, and late-stage of development for Glioma treatment.

• Glioma companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

• Glioma drugs under development based on stage, route of administration, target receptor, monotherapy or combination therapy, mechanism of action, and molecular type.

• Detailed analysis of collaborations (company–company and company–academia), licensing agreements, and financing details for future advancement of the Glioma market.

Learn more about Glioma drug opportunities in our comprehensive Glioma pipeline report @ Glioma Unmet Needs

Glioma Companies and Competitive Landscape

There are 180+ key companies developing therapies for Glioma. These include Aivita Biomedical, Inc., Denovo BioPharma, Medicenna Therapeutics, Inc., Eli Lilly and Company, Candel Therapeutics, Mustang Bio, AstraZeneca, Boehringer Ingelheim, Daiichi Sankyo, Nerviano Medical Sciences, CellabMED, Oblato, BioMed Valley Discoveries, PharmAbcine, I-Mab Biopharma, Chimerix, Aveta Biomics, Angiochem, Arog Pharmaceuticals, BioMimetix, Bexion Pharmaceuticals, CANbridge Life Sciences, Crimson Biopharma, Epitopoietic Research Corporation, Stemgen, and others — with Aivita Biomedical, Inc. having its Glioma drug candidate, AV-GBM-1, in the most advanced Phase III stage.

DelveInsight's Glioma pipeline report provides therapeutic assessment of the pipeline drugs by Route of Administration. Products have been categorized under various ROAs such as:

• Intra-articular

• Intraocular

• Intrathecal

• Intravenous

• Oral

• Parenteral

• Subcutaneous

• Topical

• Transdermal

Glioma products have been categorized under various Molecule types such as:

• Oligonucleotide

• Peptide

• Small molecule

Discover the latest advancements in Glioma treatment. Stay informed @ Glioma Market Drivers and Barriers, and Future Perspectives

Scope of the Glioma Pipeline Report

• Coverage: Global

• Glioma Companies: Aivita Biomedical, Inc., Denovo BioPharma, Medicenna Therapeutics, Inc., Eli Lilly and Company, Candel Therapeutics, Mustang Bio, AstraZeneca, Boehringer Ingelheim, Daiichi Sankyo, Nerviano Medical Sciences, CellabMED, Oblato, BioMed Valley Discoveries, PharmAbcine, I-Mab Biopharma, Chimerix, Aveta Biomics, Angiochem, Arog Pharmaceuticals, BioMimetix, Bexion Pharmaceuticals, CANbridge Life Sciences, Crimson Biopharma, Epitopoietic Research Corporation, Stemgen, and others.

• Glioma Therapies: AV-GBM-1, DB 107, MDNA55, Abemaciclib, NMS-03305293, CAN-3110, MB-101, and others.

• Glioma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination

• Glioma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Table of Contents

1. Introduction

2. Executive Summary

3. Glioma: Overview

4. Pipeline Therapeutics

5. Therapeutic Assessment

6. Glioma – DelveInsight's Analytical Perspective

7. Late Stage Products (Phase III)

8. Mid Stage Products (Phase II)

9. Early Stage Products (Phase I)

10. Preclinical and Discovery Stage Products

11. Inactive Products

12. Glioma Key Companies

13. Glioma Key Products

14. Glioma Unmet Needs

15. Glioma Market Drivers and Barriers

16. Glioma Future Perspectives and Conclusion

17. Glioma Analyst Views

18. Appendix

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Arpit Anand
Email:Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services

Telehealth Market Poised for Exceptional Growth at 31.81% CAGR Through 2034: DelveInsight | Teladoc Health, Koninklijke Philips N.V., and Siemens Healthineers

Global Telehealth Market Insights

Key global players include Teladoc Health, Inc., Siemens Healthineers AG, Cisco Systems, Inc., Koninklijke Philips N.V., IBM Corporation, Medtronic, American Well Corporation, CareCloud, Inc., GlobalMed Holding LLC., Doctor On Demand by Included Health, Inc., derma2go Deutschland GmbH, Practo, GE Healthcare, SHL Telemedicine, HP Development Company, L.P., Enghouse Systems Limited, AMD Global Telemedicine, TeleMed Global, MediOrbis, LLC., OptraScan, and others.

The global telehealth market is set for extraordinary, sustained expansion, driven by rising prevalence of chronic disorders, rapid smartphone proliferation and wearable health device adoption, and accelerating product development activities by key industry players across major geographies.

Key Takeaways

• The global telehealth market is projected to grow from USD 209,983.60 million in 2025 to USD 2,458,662.53 million by 2034, reflecting a CAGR of 31.81% during 2026–2034.

• North America is expected to dominate the market in 2025, capturing approximately 43.03% share, supported by rising incidence of medical conditions requiring ongoing care, increased product launches, supportive government initiatives, and active participation of key industry players.

• Telehealth market growth is underpinned by the growing burden of chronic conditions necessitating continuous monitoring, widespread adoption of smartphones with high-speed internet connectivity, wearable health devices enabling real-time tracking, and sustained new product development by leading market participants.

• Technological trends include AI-powered clinical decision support, remote patient monitoring via connected wearables, natural language processing for clinical documentation, 5G-enabled telemedicine, and cloud-based platform integration with electronic health record (EHR) systems to enhance workflow efficiency and care quality.

• By component, the services category is estimated to account for the largest market share of 53.78% in 2025, while teleconsulting dominates the application segment with 40.52% share; web and cloud-based delivery leads the deployment model segment with 79.23% share, and healthcare facilities account for 82.97% of the end-user segment.

• Key companies operating in the telehealth market include Teladoc Health, Inc., Siemens Healthineers AG, Cisco Systems, Inc., Koninklijke Philips N.V., IBM Corporation, Medtronic, American Well Corporation, CareCloud, Inc., GlobalMed Holding LLC., Doctor On Demand by Included Health, Inc., derma2go Deutschland GmbH, Practo, GE Healthcare, SHL Telemedicine, HP Development Company, L.P., Enghouse Systems Limited, AMD Global Telemedicine, TeleMed Global, MediOrbis, LLC., OptraScan, and others.

• Recent developments focus on AI-driven diagnostics and triage, smart clinic companions, integration with major EHR platforms, cloud-based platform authorization for federal deployment, and expanded specialist access through strategic acquisitions in key global markets.

For more recent advancements in this landscape, visit Telehealth Market Recent Developments

Telehealth Market Overview and Growth Outlook

The telehealth market is forecast to expand from USD 209,983.60 million in 2025 to USD 2,458,662.53 million by 2034, growing at a CAGR of 31.81% from 2026 to 2034. This trajectory reflects the rising global burden of cardiovascular diseases, diabetes, mental health disorders, and other chronic conditions that necessitate continuous and convenient remote care delivery, combined with the mass penetration of smartphones and connected health devices enabling seamless virtual consultations and real-time health monitoring at scale.

Stay ahead with data-driven insights on emerging technologies, evolving care models, and growth opportunities shaping the future of virtual healthcare. Dive deeper into the Telehealth market trends @ Telehealth Market Insights and Analysis.

Telehealth Market Regional Insights

North America is anticipated to hold the largest share of approximately 43.03% of the global market in 2025, driven by the rising incidence of conditions requiring ongoing care, a robust pipeline of product launches, favorable government initiatives, and deep engagement from leading industry stakeholders.

Furthermore, Europe is expected to remain a key growth engine supported by high prevalence of cardiovascular and metabolic disorders, expanding smartphone adoption — with 96% of the UK population using mobile devices as of 2024 — and a strong public healthcare infrastructure committed to reducing chronic disease burden, while Asia-Pacific is emerging as a significant growth driver fueled by China's nearly one billion smartphone users, rising mental health disorder prevalence in Japan, and active government-backed telemedicine programs.

Gain a comprehensive understanding of key regional trends, market dynamics, and competitive landscapes driving growth across global markets. Visit Telehealth Market Regional Analysis and Market Share

Telehealth Market Segmentation

• By Component: Hardware, Software, Services

• By Application: Teleconsulting, Telemonitoring, Others

• By Deployment Model: Web & Cloud-Based Delivery, On Premises Delivery, Hybrid

• By Speciality: Cardiology, Dermatology, Mental Health, Others

• By End-Users: Healthcare Facilities, Homecare Settings

• By Geography: North America, Europe, Asia-Pacific, Rest of the World

Telehealth Market Competitive Landscape

The competitive landscape is moderately concentrated, with a growing number of established healthcare IT companies, traditional telemedicine providers, and innovative start-ups competing for market share across virtual care platforms, remote patient monitoring, AI-enabled diagnostics, and integrated digital care ecosystems.

Key global players include Teladoc Health, Inc., Siemens Healthineers AG, Cisco Systems, Inc., Koninklijke Philips N.V., IBM Corporation, Medtronic, American Well Corporation, CareCloud, Inc., GlobalMed Holding LLC., Doctor On Demand by Included Health, Inc., derma2go Deutschland GmbH, Practo, GE Healthcare, SHL Telemedicine, HP Development Company, L.P., Enghouse Systems Limited, AMD Global Telemedicine, TeleMed Global, MediOrbis, LLC., OptraScan, and others.

Which company is expected to dominate the Telehealth market? Know @ Telehealth Competitive Landscape.

Key Features of DelveInsight's Telehealth Market Report

• Detailed market sizing and forecasts from 2025 to 2034 at global and regional levels, including revenue projections and CAGR analysis.

• Granular assessment of market contribution by major regions such as North America, Europe, Asia-Pacific, and Rest of the World, with country-level breakdowns across the US, Canada, UK, Germany, France, China, Japan, India, Australia, and others.

• Coverage of key segments including component (hardware, software, services), application (teleconsulting, telemonitoring), deployment model (web & cloud-based, on-premises, hybrid), specialty, and end-user.

• Evaluation of usage across care settings, including hospitals, clinics, government health centers, and homecare environments where telehealth is increasingly integrated into mainstream care delivery.

• Detailed discussion on why North America is expected to dominate, including drivers such as high chronic disease burden, supportive regulatory frameworks, and active product launch activity by key players.

• Insight into Europe's and Asia-Pacific's growth dynamics, including chronic condition prevalence, smartphone and connectivity penetration, and government-led digital health initiatives.

• Systematic coverage of demand drivers including rising cardiovascular and metabolic disease burden, global smartphone proliferation, and continuous product innovation by telehealth companies.

• Identification of evolving opportunities around AI-powered diagnostics and triage, 5G-enabled telemedicine, big data analytics, wearable device integration, and cybersecurity advancements.

• Profiles and strategic analysis of major companies in the telehealth landscape, including recent mergers, acquisitions, partnerships, and product launches.

• Assessment of market concentration, technology adoption trends, tariff impact analysis, and strategic levers for market entry or expansion.

Request Custom Analysis or Speak to Our Analyst @ Telehealth Market Report

Table of Contents

1. Telehealth Market Report Introduction

2. Telehealth Market Executive Summary

3. Telehealth Market Key Factors Analysis

4. Telehealth Market: Impact Analysis

5. Telehealth Market Regulatory Analysis

6. Telehealth Market Porter’s Five Forces Analysis

7. Telehealth Market Assessment

8. Telehealth Market Competitive Landscape

9. Startup Funding & Investment Trends

10. Telehealth Market Company and Product Profiles

11. KOL Views

12. Project Approach

13. About DelveInsight

14. Disclaimer & Contact Us

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Arpit Anand
Email:Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services

Breast Cancer Clinical Trial Gains Momentum: 250+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight

DelveInsight’s “Breast Cancer Pipeline Insight 2026” report provides comprehensive insights about 250+ Breast Cancer companies and 300+ pipeline drugs in the Breast Cancer pipeline landscape. It covers the Breast Cancer pipeline drugs profiles, including clinical and nonclinical stage products. It also covers the Breast Cancer pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Discover the latest drugs and treatment options in the Breast Cancer Pipeline. Dive into DelveInsight's comprehensive report today! @ Breast Cancer Pipeline Outlook

Key Takeaways from the Breast Cancer Pipeline Report

• On March 16, 2026- Merck Sharp & Dohme LLC announced a phase 3 study is to learn if people who receive patritumab deruxtecan (also known as HER3-DXd and MK-1022) live longer overall or without the cancer growing/spreading, compared to people who receive chemotherapy or a different drug called trastuzumab deruxtecan.
• On March 11, 2026- Bristol-Myers Squibb initiated a phase 2/3 study is to assess the efficacy and safety of iza-bren, a bi-specific antibody-drug conjugate against EGFR and HER3 with a topoisomerase inhibitor payload versus treatment of physician's choice (TPC) (paclitaxel, nab-paclitaxel, carboplatin plus gemcitabine, and capecitabine) for the treatment of first-line metastatic triple-negative breast cancer (TNBC) or estrogen receptor (ER)-low, human epidermal growth factor receptor 2 (HER2)-negative BC patients who are not candidates for anti-PD(L)1 therapy and endocrine therapies.
• On March 04, 2026- Pfizer conducted a clinical study is to learn about the safety and effects of the study medicine (called disitamab vedotin) for the possible treatment of people with breast cancer that is hard to treat and has spread in the body (advanced cancer).
• DelveInsight’s Breast Cancer pipeline report depicts a robust space with 250+ Breast Cancer companies working to develop 300+ pipeline therapies for Breast Cancer treatment.
• The leading Breast Cancer Companies such as Tanvex Biopharma, Sichuan Kelun-Biotech Biopharmaceutical, Shanghai Henlius Biotech, Byondis, CSPC Ouyi Pharmaceutical Co., Ltd., Pfizer, Jazz Pharmaceuticals, Biostar Pharma, Inc., Chia Tai Tianqing Pharmaceutical Group, InventisBio, Coherent Biopharma, Shanghai Jiaolian Drug Research and Development Co., Ltd., Ambrx, MediLink Therapeutics (Suzhou) Co., Ltd., Tasly Pharmaceutical Group, Convalife (Shanghai) Co., Ltd., Merck & Co., AstraZeneca, Aclaris Therapeutics, Boehringer Ingelheim, NovaOnco Therapeutics Co., Ltd., Verastem Oncology, Ellipses Pharma, Shenzhen Yangli Pharmaceutical Technology Co., Ltd., TYK Medicine, Ascendis Pharma, ExpreS2ion Biotechnologies, Mersana Therapeutics, Exelixis, Shenzhen Celconta Life Science, Beijing Wehand-Bio Pharmaceutical, VM Oncology, Hinova Pharmaceuticals, OS Therapies, and Syntab Therapeutics and others.
• Promising Breast Cancer Pipeline Therapies such as Oraxol, ARV-471, Ribociclib, E7389, Trastuzumab, GM-CSF, GM-CSF, Trastuzumab, Paclitaxel, Gemcitabine/Carboplatin, Iniparib, and others.

Stay ahead with the most recent pipeline outlook for Breast Cancer. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Breast Cancer Treatment

The Breast Cancer Pipeline Report provides disease overview, pipeline scenario and therapeutic assessment of the key pipeline therapies in this domain. The Breast Cancer Pipeline Report also highlights the unmet needs with respect to the Breast Cancer.

Breast Cancer Overview

Breast cancer is a malignant tumor that originates in the cells of the breast, most commonly in the ducts (ductal carcinoma) or lobules (lobular carcinoma). It is one of the most prevalent cancers among women worldwide, although it can also occur in men. Risk factors include age, family history, genetic mutations such as BRCA1 and BRCA2, hormonal factors, obesity, and lifestyle choices. Breast cancer can range from localized, slow-growing tumors to aggressive types that metastasize to other parts of the body.

Breast Cancer Emerging Drugs Profile

• Vepdegestrant (ARV-471): Pfizer/ Arvinas

Vepdegestrant is an investigational, orally bioavailable PROteolysis TArgeting Chimera (PROTAC) protein degrader designed to specifically target and degrade the estrogen receptor (ER) for the treatment of patients with ER-positive (ER+)/human epidermal growth factor receptor 2 (HER2)-negative (ER+/HER2-) breast cancer. Vepdegestrant is being developed as a potential monotherapy for ER+/HER2- advanced or metastatic breast cancer with estrogen receptor 1 (ESR1) mutations in the second line-plus setting. The U.S. Food and Drug Administration (FDA) has granted vepdegestrant Fast Track designation as a monotherapy in the treatment of adults with ER+/HER2- advanced or metastatic breast cancer previously treated with endocrine-based therapy. Currently the drug is in Preregistration stage of development for the treatment of ER+/HER2- Metastatic Breast Cancer, ER+/HER2- Early Breast Cancer.

• Utidelone: Biostar Pharma, Inc.

Utidelone (UTD1), developed by Biostar Pharma, is a genetically engineered epothilone analog and next-generation microtubule inhibitor that received approval in China in March 2021 for metastatic breast cancer. Unlike taxanes, it binds a different site on microtubules, enabling it to overcome taxane resistance, demonstrate strong antitumor activity, and maintain low hematologic toxicity—showing both progression-free survival (PFS) and overall survival (OS) benefits in heavily pretreated patients when combined with capecitabine. Ongoing global trials include expanding indications such as neoadjuvant breast cancer, brain metastases, and even oral formulations to enhance convenience and broaden therapeutic impact. Currently the drug is in Phase III stage of development for the treatment of advanced breast cancer, Breast cancer neoadjuvant and breast cancer brain metastasis.

• ARX788: Ambrx, Inc.

ARX788, an anti-HER2 ADC currently being studied broadly in breast cancer, gastric/GEJ cancer and other solid tumor clinical trials. ARX788 is a homogeneous and highly stable ADC, which targets the HER2 receptor and contains two AS269 cytotoxic payloads site-specifically conjugated to a trastuzumab-based antibody. ARX788 was designed to maximize potential anti-tumor activity by optimizing the number and position of the payloads and the chemical bonds that conjugate the payloads to the antibody. AS269, proprietary payload, is a tubulin inhibitor specifically designed to form a highly stable covalent bond with our SAAs and kill tumor cells only upon entry into the cell when aided by the conjugated targeting antibody, thereby limiting off-target effects on healthy tissue. Currently, the drug is in the Phase II/III stage of its development for the treatment of Triple Negative Breast Cancer.

• TSL-1502: Jiangsu Tasly Diyi Pharmaceutical Co., Ltd.

TSL-1502 is a pro-drug and its metabolite TSL-1502M has higher localized concentration at cancer sites with more potency, thus, our preclinical studies demonstrated that TSL-1502’s anticancer activity is superior to competitor(s) while having a much wider therapeutic window. TSL-1502 is a small molecule drug, ready for clinical investigation (INDs) under both Chinese FDA (cFDA) and US FDA regulations. A phase II clinical trial will be managed and conducted in the USA. TSL-1502 is positioned to have strong PCT patent protections. Patents cover chemical structure, chiral auxiliary structures, crystal form, synthesize methods, and all potential indications. Currently the drug is in Phase II stage of its development for the treatment of HER2-negative Locally Advanced or Metastatic Breast Cancer Patients With Germline BRCA Mutations.

• PF-07104091: Pfizer

PF-07104091, also known as tegtociclib, is a first-in-class, orally administered, selective CDK2 inhibitor being developed for the treatment of various advanced solid tumors, with a particular focus on hormone receptor-positive (HR+)/HER2-negative metastatic breast cancer that has progressed after prior CDK4/6 inhibitor therapy. By selectively inhibiting CDK2, PF-07104091 aims to induce cell cycle arrest through reduced phosphorylation of retinoblastoma protein (Rb) and other downstream targets, offering a novel approach to overcoming resistance to existing CDK4/6 inhibitors. Early-phase clinical trials have demonstrated that PF-07104091 is generally well tolerated and shows preliminary antitumor activity in heavily pretreated patients, with ongoing studies evaluating its use both as monotherapy and in combination with other agents such as fulvestrant and palbociclib. Currently, the drug is in the Phase II stage of its development for the treatment of Breast Cancer.

• XL092: Edgewood Oncology Inc.

XL092 is a third-generation oral tyrosine kinase inhibitor that inhibits the activity of receptor tyrosine kinases implicated in cancer growth and spread, including VEGF receptors, MET, AXL and MER. These receptor tyrosine kinases are involved in both normal cellular function and in pathologic processes such as oncogenesis, metastasis, tumor angiogenesis and resistance to multiple therapies, including immune checkpoint inhibitors. Zanzalintinib is currently being developed for the treatment of advanced solid tumors, including genitourinary, colorectal and head and neck cancers. The drug is currently being evaluated under Phase I/II stage of development for the treatment of patients suffering from breast cancer.

Explore groundbreaking therapies and clinical trials in the Breast Cancer Pipeline. Access DelveInsight's detailed report now! @ New Breast Cancer Drugs

Breast Cancer Companies

Tanvex Biopharma, Sichuan Kelun-Biotech Biopharmaceutical, Shanghai Henlius Biotech, Byondis, CSPC Ouyi Pharmaceutical Co., Ltd., Pfizer, Jazz Pharmaceuticals, Biostar Pharma, Inc., Chia Tai Tianqing Pharmaceutical Group, InventisBio, Coherent Biopharma, Shanghai Jiaolian Drug Research and Development Co., Ltd., Ambrx, MediLink Therapeutics (Suzhou) Co., Ltd., Tasly Pharmaceutical Group, Convalife (Shanghai) Co., Ltd., Merck & Co., AstraZeneca, Aclaris Therapeutics, Boehringer Ingelheim, NovaOnco Therapeutics Co., Ltd., Verastem Oncology, Ellipses Pharma, Shenzhen Yangli Pharmaceutical Technology Co., Ltd., TYK Medicine, Ascendis Pharma, ExpreS2ion Biotechnologies, Mersana Therapeutics, Exelixis, Shenzhen Celconta Life Science, Beijing Wehand-Bio Pharmaceutical, VM Oncology, Hinova Pharmaceuticals, OS Therapies, and Syntab Therapeutics and others.

Breast Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration

• Intravenous
• Subcutaneous
• Oral
• Intramuscular

Breast Cancer Products have been categorized under various molecular types such as

• Monoclonal antibody
• Small molecule
• Peptide

Unveil the future of Breast Cancer Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight's expert analysis @ Breast Cancer Market Drivers and Barriers

Scope of the Breast Cancer Pipeline Report

• Coverage- Global
• Breast Cancer Companies- Tanvex Biopharma, Sichuan Kelun-Biotech Biopharmaceutical, Shanghai Henlius Biotech, Byondis, CSPC Ouyi Pharmaceutical Co., Ltd., Pfizer, Jazz Pharmaceuticals, Biostar Pharma, Inc., Chia Tai Tianqing Pharmaceutical Group, InventisBio, Coherent Biopharma, Shanghai Jiaolian Drug Research and Development Co., Ltd., Ambrx, MediLink Therapeutics (Suzhou) Co., Ltd., Tasly Pharmaceutical Group, Convalife (Shanghai) Co., Ltd., Merck & Co., AstraZeneca, Aclaris Therapeutics, Boehringer Ingelheim, NovaOnco Therapeutics Co., Ltd., Verastem Oncology, Ellipses Pharma, Shenzhen Yangli Pharmaceutical Technology Co., Ltd., TYK Medicine, Ascendis Pharma, ExpreS2ion Biotechnologies, Mersana Therapeutics, Exelixis, Shenzhen Celconta Life Science, Beijing Wehand-Bio Pharmaceutical, VM Oncology, Hinova Pharmaceuticals, OS Therapies, and Syntab Therapeutics and others.
• Breast Cancer Pipeline Therapies- Oraxol, ARV-471, Ribociclib, E7389, Trastuzumab, GM-CSF, GM-CSF, Trastuzumab, Paclitaxel, Gemcitabine/Carboplatin, Iniparib, and others.
• Breast Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Breast Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Get the latest on Breast Cancer Therapies and clinical trials. Download DelveInsight's in-depth pipeline report today! @ Breast Cancer Companies, Key Products and Unmet Needs

Table of Contents

1. Introduction
2. Executive Summary
3. Breast Cancer: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Breast Cancer– DelveInsight’s Analytical Perspective
7. Late Stage Products (Registration)
8. Vepdegestrant (ARV-471): Pfizer/ Arvinas
9. Mid Stage Products (Phase II)
10. PF-07104091: Pfizer
11. Early Stage Products (Phase I/II)
12. XL092: Edgewood Oncology Inc.
13. Preclinical and Discovery Stage Products
14. Drug Name: Company Name
15. Inactive Products
16. Breast Cancer Key Companies
17. Breast Cancer Key Products
18. Breast Cancer- Unmet Needs
19. Breast Cancer- Market Drivers and Barriers
20. Breast Cancer- Future Perspectives and Conclusion
21. Breast Cancer Analyst Views
22. Breast Cancer Key Companies
23. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/report-store/breast-cancer-pipeline-insight

Wet-Age Related Macular Degeneration Treatment Pipeline Shows Strong Momentum as 60+ Pharma Companies in the Race | DelveInsight

DelveInsight’s “Wet-AMD Pipeline Insight 2026” report provides comprehensive insights about 60+ companies and 75+ pipeline drugs in the Wet-AMD pipeline landscape. It covers the Wet-AMD Pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Wet-AMD Pipeline Therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Curious about the latest updates in the Wet-AMD Pipeline? Click here to explore the therapies and trials making headlines @ Wet-AMD Pipeline Outlook Report

Key Takeaways from the Wet-AMD Pipeline Report

• On March 05, 2026- Innostellar Biotherapeutics Co. Ltd initiated a Phase III, randomized, open-label, active-controlled study to evaluate the efficacy and safety of subretinal injection of LX102 in participants with neovascular age-related macular degeneration. The study will evaluate a single subretinal injection of LX102 compared to an active comparator. The primary endpoint of this study is the mean change from D0 in BCVA based on an average at weeks 40 and 48.
• On March 03, 2026- EyePoint Pharmaceuticals Inc. announced a phase 3 randomized, double -masked study comparing the efficacy of EYP-1901 against Aflibercept.
• DelveInsight’s Wet-AMD Pipeline report depicts a robust space with 60+ active players working to develop 75+ pipeline therapies for Wet-AMD treatment.
• The leading Wet-AMD Companies such as Sylentis, Molecular Partners, Sam Chun Dang Pharm, Generium, Alvotech, Adverum Biotechnologies, EyePoint Pharmaceuticals, 4D Molecular Therapeutics, OliX Pharmaceuticals, Kyowa Kirin, Exonate and others.
• Promising Wet-AMD Therapies such as NT-101 0.05 mM, AVT06, RGX-314, ABP 938, Aflibercept, HX9428 tablet, FT-003, Ranibizumab, Tarcocimab Tedromer, LFG316 and others.

Want to know which companies are leading innovation in Wet-AMD? Dive into the full pipeline insights @ Wet-AMD Clinical Trials Assessment

The Wet-AMD Pipeline Report provides disease overview, pipeline scenario and therapeutic assessment of the key pipeline therapies in this domain. The Wet-AMD Pipeline Report also highlights the unmet needs with respect to the Wet-AMD.

Wet-AMD Overview

Wet Age-related Macular Degeneration (AMD) is a chronic eye disease that affects the macula, the central part of the retina responsible for sharp, detailed vision. It is a more severe form of AMD compared to the dry type and progresses rapidly, leading to significant vision loss if untreated. Wet AMD occurs when abnormal blood vessels grow under the macula, leaking blood or fluid, which disrupts retinal function and causes scarring. This condition primarily affects older adults, usually over the age of 50, and is a leading cause of central vision loss in this age group.

Wet-AMD Emerging Drugs Profile

• RGX-314: REGENXBIO

RGX-314 is a one-time subretinal treatment that includes the NAV AAV8 vector containing a gene encoding for a monoclonal antibody fragment. The expressed protein is designed to neutralize vascular endothelial growth factor (VEGF) activity, modifying the pathway for the formation of new leaky blood vessels and retinal fluid accumulation. RGX-314 is being developed as a potentially one-time treatment for wet AMD, diabetic retinopathy, and other additional chronic retinal conditions treated with anti-VEGF. REGENXBIO is advancing research in two separate routes of administration of RGX-314 to the eye, through a standardized subretinal delivery procedure as well as delivery to the suprachoroidal space. Currently, the drug is in the Phase III stage of its development for the treatment of Wet Age-Related Macular Degeneration (AMD).

• CLS-AX: Clearside Biomedical

CLS‑AX is a proprietary axitinib injectable suspension delivered via Clearside’s suprachoroidal space (SCS) Microinjector®, designed as a long-acting treatment for wet age-related macular degeneration (wet AMD). It’s a potent, pan‑VEGF tyrosine kinase inhibitor (TKI) that offers targeted, durable delivery behind the retina, potentially reducing injection frequency while maintaining stable visual acuity. CLS‑AX has demonstrated positive safety and efficacy in Phase IIb (ODYSSEY) results and is currently being advanced toward a Phase III development program

• SYL1801: Sylentis

SYL1801 is a small interfering RNA (siRNA) in the non-clinical research phase. This siRNA, by means of mechanism of action based on RNA interference (RNAi), inhibits the synthesis of NRARP (Notch-regulated ankyrin repeat-containing protein). NRARP is directly involved in the pathophysiology of choroidal neovascularization, i.e. the abnormal formation of new vessels from the choroid into the retina. It is a common hallmark of several retinal diseases such as age-related macular degeneration (AMD) or diabetic retinopathy (DR). During angiogenesis (new vessel formation), NRARP integrates the Notch and Wnt signaling pathways by controlling stalk cell proliferation to stabilize new endothelial cell connections . Currently the drug in in Phase II stage of its treatment of Wet Age-Related Macular Degeneration (Wet-AMD).

• IBI 333: Innovent Biologics

IBI‑333 is an investigational bispecific fusion protein developed by Innovent Biologics targeting both VEGF‑A and VEGF‑C. It’s currently in Phase I trials (for neovascular age‑related macular degeneration), where it is delivered via intravitreal injection to block dual angiogenic pathways and potentially overcome resistance seen with VEGF‑A monotherapy. Currently the drug in in Phase I stage of its treatment of Wet Age-Related Macular Degeneration (Wet-AMD).

If you’re tracking ongoing Wet-AMD Clinical trials, this press release is a must-read. Tap to see the breakthroughs @ Wet-AMD Treatment Drugs

The Wet-AMD Pipeline report provides insights into:-

• The report provides detailed insights about companies that are developing therapies for the treatment of Wet-AMD with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Wet-AMD Treatment.
• Wet-AMD Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Wet-AMD Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Wet-AMD market.

Wet-AMD Companies

Sylentis, Molecular Partners, Sam Chun Dang Pharm, Generium, Alvotech, Adverum Biotechnologies, EyePoint Pharmaceuticals, 4D Molecular Therapeutics, OliX Pharmaceuticals, Kyowa Kirin, Exonate and others.

Wet-AMD Pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as,

• Intravenous
• Subcutaneous
• Oral
• Intramuscular

Wet-AMD Products have been categorized under various Molecule types such as,

• Monoclonal antibody
• Small molecule
• Peptide

From emerging drug candidates to competitive intelligence, the Wet-AMD Pipeline Report covers it all – check it out now @ Wet-AMD Market Drivers and Barriers, and Future Perspectives

Scope of the Wet-AMD Pipeline Report

• Coverage- Global
• Wet-AMD Companies- Sylentis, Molecular Partners, Sam Chun Dang Pharm, Generium, Alvotech, Adverum Biotechnologies, EyePoint Pharmaceuticals, 4D Molecular Therapeutics, OliX Pharmaceuticals, Kyowa Kirin, Exonate and others.
• Wet-AMD Therapies- NT-101 0.05 mM, AVT06, RGX-314, ABP 938, Aflibercept, HX9428 tablet, FT-003, Ranibizumab, Tarcocimab Tedromer, LFG316 and others.
• Wet-AMD Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Wet-AMD Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Stay ahead in Healthcare Research – discover what’s next for the Wet-AMD Treatment landscape in this detailed analysis @ Wet-AMD Emerging Drugs and Major Players

Table of Contents

1. Introduction
2. Executive Summary
3. Wet Age-Related Macular Degeneration (Wet-AMD): Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Wet Age-Related Macular Degeneration (Wet-AMD)– DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. RGX-314: REGENXBIO
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. SYL1801: Sylentis
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. IBI 333: Innovent Biologics
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. Drug Name: Company Name
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Wet Age-Related Macular Degeneration (Wet-AMD) Key Companies
21. Wet Age-Related Macular Degeneration (Wet-AMD) Key Products
22. Wet Age-Related Macular Degeneration (Wet-AMD)- Unmet Needs
23. Wet Age-Related Macular Degeneration (Wet-AMD)- Market Drivers and Barriers
24. Wet Age-Related Macular Degeneration (Wet-AMD)- Future Perspectives and Conclusion
25. Wet Age-Related Macular Degeneration (Wet-AMD) Analyst Views
26. Wet Age-Related Macular Degeneration (Wet-AMD) Key Companies
27. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/report-store/wet-age-related-macular-degeneration-wet-amd-pipeline-insight

Dravet Syndrome Clinical Trial Pipeline Shows Potential with Active Contributions from 10+ Key Companies | DelveInsight

DelveInsight’s, “Dravet syndrome Pipeline Insight 2026” report provides comprehensive insights about 10+ companies and 12+ pipeline drugs in Dravet syndrome pipeline landscape. It covers the Dravet Syndrome pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Dravet Syndrome pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Discover the latest drugs and treatment options in the Dravet Syndrome Pipeline. Dive into DelveInsight's comprehensive report today! @ Dravet Syndrome Pipeline Outlook

Key Takeaways from the Dravet Syndrome Pipeline Report

• On March 17, 2026- Jazz Pharmaceuticals initiated a study will monitor for potential chronic liver injury and liver fibrosis, in participants treated with cannabidiol oral solution.
• On March 12, 2026- Longboard Pharmaceuticals announced a phase 3 study to investigate the efficacy, safety, and tolerability of LP352 in the treatment of seizures in children and adults with DS. The study consists of 3 main phases: Screening, Titration period, and Maintenance period, followed by a Taper period and Follow-Up. Participants will be randomized to LP352 or placebo. The total duration of the study will be approximately 24 months.
• DelveInsight’s Dravet Syndrome pipeline report depicts a robust space with 10+ active players working to develop 12+ pipeline therapies for Dravet Syndrome treatment.
• The leading Dravet Syndrome Companies such as Hinova Pharmaceuticals, Lantheus, Janux Therapeutics, Tagworks Pharmaceuticals, AstraZeneca, Xencor, Cardiff Oncology, Madison Vaccines, Bayer, Olema Oncology, Eli Lilly and Company, Curium, Pfizer, Regeneron Pharmaceuticals, PendreaBio, Momotaro-Gene, Norroy Bioscience, Orion Corporation, Epizyme, Barinthus Biotherapeutics, Twinpig Biolab, Oxford Vacmedix, Roche, ImaginAb, Halda THERAPEUTICS, Novartis, Kyinno Biotechnology and others.
• Promising Dravet Syndrome Pipeline Therapies such as Ganaxolone, Fenfluramine, Zorevunersen, ETX101, STK-001, Clemizole HCl, LP352, Verapamil, ZX008 and others.

Stay ahead with the most recent pipeline outlook for Dravet Syndrome. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Dravet Syndrome Treatment Drugs

Dravet Syndrome Emerging Drugs Profile

• Soticlestat : Takeda

Soticlestat is a potent, highly selective, first-in-class inhibitor of the enzyme cholesterol 24-hydroxylase (CH24H), with the potential to reduce seizure susceptibility and improve seizure control. CH24H is predominantly expressed in the brain, where it converts cholesterol into 24S-hydroxycholesterol (24HC) to adjust the homeostatic balance of brain cholesterol. 24HC is a positive allosteric modulator of the NMDA receptor and modulates glutamatergic signaling associated with epilepsy. Currently, the drug is in the Phase III stage of its development for the treatment of Dravet syndrome and Lennox-Gastaut syndrome.

• EPX-100: Harmony Biosciences

EPX-100, clemizole hydrochloride, is under development for the treatment of Dravet syndrome (DS) and Lennox-Gastaut syndrome (LGS). EPX-100 acts by targeting central 5-hydroxytryptamine receptors to modulate serotonin signaling. The drug candidate is administered orally twice a day in a liquid formulation and has been developed based on a proprietary phenotype-based zebrafish drug screening platform.1 DS is caused by a loss of function mutation in the SCN1A gene, and scn1 mutant zebrafish replicate the genetic etiology and phenotype observed in the majority of DS patients. The scn1Lab mutant zebrafish model that expresses voltage gated sodium channels has been used for high-throughput screening of compounds that modulate Nav1.1 in the central nervous system. Currently, the drug is in the Phase II stage of its development for the treatment of Dravet syndrome and Lennox-Gastaut syndrome.

The Dravet Syndrome Pipeline Report Provides Insights into

• The report provides detailed insights about companies that are developing therapies for the treatment of Dravet Syndrome with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Dravet Syndrome Treatment.
• Dravet Syndrome Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Dravet Syndrome Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Dravet Syndrome market

Explore groundbreaking therapies and clinical trials in the Dravet Syndrome Pipeline. Access DelveInsight's detailed report now! @ New Dravet Syndrome Drugs

Dravet Syndrome Companies

Hinova Pharmaceuticals, Lantheus, Janux Therapeutics, Tagworks Pharmaceuticals, AstraZeneca, Xencor, Cardiff Oncology, Madison Vaccines, Bayer, Olema Oncology, Eli Lilly and Company, Curium, Pfizer, Regeneron Pharmaceuticals, PendreaBio, Momotaro-Gene, Norroy Bioscience, Orion Corporation, Epizyme, Barinthus Biotherapeutics, Twinpig Biolab, Oxford Vacmedix, Roche, ImaginAb, Halda THERAPEUTICS, Novartis, Kyinno Biotechnology and others.

Dravet Syndrome pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

Dravet Syndrome Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

Unveil the future of Dravet Syndrome Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight's expert analysis @ Dravet Syndrome Market Drivers and Barriers

Scope of the Dravet Syndrome Pipeline Report

• Coverage- Global
• Dravet Syndrome Companies- Hinova Pharmaceuticals, Lantheus, Janux Therapeutics, Tagworks Pharmaceuticals, AstraZeneca, Xencor, Cardiff Oncology, Madison Vaccines, Bayer, Olema Oncology, Eli Lilly and Company, Curium, Pfizer, Regeneron Pharmaceuticals, PendreaBio, Momotaro-Gene, Norroy Bioscience, Orion Corporation, Epizyme, Barinthus Biotherapeutics, Twinpig Biolab, Oxford Vacmedix, Roche, ImaginAb, Halda THERAPEUTICS, Novartis, Kyinno Biotechnology and others.
• Dravet Syndrome Pipeline Therapies- Ganaxolone, Fenfluramine, Zorevunersen, ETX101, STK-001, Clemizole HCl, LP352, Verapamil, ZX008 and others.
• Dravet Syndrome Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Dravet Syndrome Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Get the latest on Dravet Syndrome Therapies and clinical trials. Download DelveInsight's in-depth pipeline report today! @ Dravet Syndrome Companies, Key Products and Unmet Needs

Table of Contents

1. Introduction
2. Executive Summary
3. Dravet Syndrome: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Dravet Syndrome– DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. Soticlestat : Takeda
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. EPX-100: Harmony Biosciences
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I/II)
14. Drug Name: Company Name
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. Drug Name: Company Name.
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Comparative Analysis
21. Dravet Syndrome Key Companies
22. Dravet Syndrome Key Products
23. Dravet Syndrome- Unmet Needs
24. Dravet Syndrome- Market Drivers and Barriers
25. Dravet Syndrome- Future Perspectives and Conclusion
26. Dravet Syndrome Analyst Views
27. Dravet Syndrome Key Companies
28. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/report-store/dravet-syndrome-pipeline-insight

Malignant Ascites Clinical Trial Pipeline Gains Momentum: 5+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight

elveInsight’s, “Malignant Ascites Pipeline Insights 2026” Report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Malignant Ascites pipeline landscape. It covers the Malignant Ascites pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Malignant Ascites pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Dive into DelveInsight's comprehensive report today! @ https://www.delveinsight.com/sample-request/malignant-ascites-pipeline-insight

Key Takeaways from the Malignant Ascites Pipeline Report

• In February 2026, Dong Sheng Zhang conducted a Phase II Expansion Stage To evaluate the efficacy and safety of liposomal irinotecan as monotherapy or in combination with recombinant modified human tumor necrosis factor or bevacizumab, in the treatment of malignant peritoneal effusion in patients who have failed prior standard therapy.
• In January 2026, the National Cancer Institute (NCI) announced a study fluids and blood of people with cancer. The fluids are from the abdomen and around the lungs. Studying these might help researchers learn about the biology of cancer. This may lead to better ways to treat cancer.
• DelveInsight’s Malignant Ascites pipeline report depicts a robust space with 100+ active players working to develop 100+ pipeline therapies for Malignant Ascites treatment.
• The leading Malignant Ascites Companies such as Clover Biopharmaceuticals, YZY Biopharma, Sorrento Therapeutics, Inc., Simcere, PharmaCyte Biotech, Linton Pharma and others.
• Promising Malignant Ascites Pipeline Therapies such as SIM0388, Pembrolizumab, Nivolumab, M701, Paracentesis, Serplulimab, Bevacizumab, Molgramostim, and others.

Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Malignant Ascites Treatment Drugs

The Malignant Ascites Pipeline Report provides disease overview, pipeline scenario, and therapeutic assessment of the key pipeline therapies in this domain. The Malignant Ascites Pipeline Report also highlights the unmet needs with respect to Malignant Ascites.

Malignant Ascites Overview

Malignant Ascites is a serious clinical condition characterized by the abnormal accumulation of fluid in the peritoneal cavity due to underlying cancer. It most commonly occurs in advanced-stage malignancies, particularly ovarian cancer, gastrointestinal cancers (such as colorectal and gastric cancer), pancreatic cancer, hepatocellular carcinoma, and breast cancer. The presence of malignant ascites often indicates disease progression and poor prognosis, making it a significant concern in oncology care.

Malignant Ascites Emerging Drugs Profile

• SCB-313: Clover Biopharmaceuticals

With the Trimer-Tag™ technology platform, the company have developed SCB-313 as a covalently-linked, native-like trimeric fusion protein which is structurally and functionally differentiated from the dimeric antibody-based structures and other native ligand-based candidates targeting this pathway. They are developing SCB-313 for the treatment of malignant ascites (MA), malignant pleural effusions (MPE), and peritoneal carcinomatosis (PC) to address global unmet medical need of intracavitary malignancies. The drug is currently in Phase I stage of clinical trial evaluation to treat malignant ascites.

The Malignant Ascites Pipeline Report Provides Insights into

• The report provides detailed insights about companies that are developing therapies for the treatment of Malignant Ascites with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Malignant Ascites Treatment.
• Malignant Ascites Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Malignant Ascites Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Malignant Ascites market

Explore groundbreaking therapies and clinical trials in the Malignant Ascites Pipeline @ New Malignant Ascites Drugs

Malignant Ascites Companies

Clover Biopharmaceuticals, YZY Biopharma, Sorrento Therapeutics, Inc., Simcere, PharmaCyte Biotech, Linton Pharma and others.

Malignant Ascites Pipeline Report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical

Malignant Ascites Products have been categorized under various Molecule types such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

Learn about new drugs, pipeline developments, and key companies with DelveInsight's expert analysis @ Malignant Ascites Market Drivers and Barriers

Scope of the Malignant Ascites Pipeline Report

• Coverage- Global
• Malignant Ascites Companies- Clover Biopharmaceuticals, YZY Biopharma, Sorrento Therapeutics, Inc., Simcere, PharmaCyte Biotech, Linton Pharma and others.
• Malignant Ascites Pipeline Therapies- SIM0388, Pembrolizumab, Nivolumab, M701, Paracentesis, Serplulimab, Bevacizumab, Molgramostim, and others.
• Malignant Ascites Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Malignant Ascites Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Get the latest on Malignant Ascites Therapies and clinical trials. Download DelveInsight's in-depth pipeline report today! @ Malignant Ascites Companies, Key Products and Unmet Needs

Table of Contents

1. Introduction
2. Executive Summary
3. Malignant ascites: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Malignant ascites – DelveInsight’s Analytical Perspective
7. Mid Stage Products (Phase II)
8. Early Stage Products (Phase I)
9. SCB-313: Clover Biopharmaceuticals
10. Inactive Products
11. Malignant ascites Key Companies
12. Malignant ascites Key Products
13. Malignant ascites- Unmet Needs
14. Malignant ascites- Market Drivers and Barriers
15. Malignant ascites- Future Perspectives and Conclusion
16. Malignant ascites Analyst Views
17. Malignant ascites Key Companies
18. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/report-store/malignant-ascites-pipeline-insight

Triple Negative Breast Cancer Clinical Trial Pipeline Expands as 165+ Companies Driving Innovation in the Therapeutics | DelveInsight

DelveInsight’s “Triple Negative Breast Cancer Pipeline Insight 2026” report provides comprehensive insights about 165+ companies and 170+ pipeline drugs in the Triple Negative Breast Cancer pipeline landscape. It covers the Triple Negative Breast Cancer Pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Triple Negative Breast Cancer pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Explore the comprehensive insights by DelveInsight and stay ahead in understanding the Triple Negative Breast Cancer Treatment Landscape. Click here to read more @ Triple Negative Breast Cancer Pipeline Outlook

Key Takeaways from the Triple Negative Breast Cancer Pipeline Report

• On March 16, 2026- Akeso announced a phase 2 study is to evaluate the efficacy, safety, and pharmacokinetics of AK117/AK112 administered with chemotherapy in participants with locally advanced or metastatic triple-negative breast cancer (TNBC) who have not received prior systemic therapy for metastatic breast cancer (mBC).
• On March 13, 2026- Merck Sharp & Dohme LLC initiated a phase 3 study is to learn if people treated with sacituzumab tirumotecan alone or with pembrolizumab live longer overall or without the cancer growing or spreading compared to people treated with chemotherapy.
• DelveInsight’s Triple Negative Breast Cancer Pipeline analysis depicts a robust space with 165+ active players working to develop 170+ pipeline treatment therapies.
• The leading Triple Negative Breast Cancer Companies such as Shanghai Henlius Biotech, Jiangsu HengRui Medicine Co., Ltd., G1 Therapeutics, Inc., Infinity Pharmaceuticals, HiberCell, Inc., Zenith Epigenetics, BioLite, Inc., Abbisko Therapeutics, Phoenix Molecular Designs, OncoTherapy Science, ModernaTX, Inc, and others.
• Promising Triple Negative Breast Cancer Pipeline Therapies such as Nanosomal Docetaxel Lipid Suspension (75 mg/m2), Taxotere® (100 mg/m2), B013+Nab-Paclitaxel, ZEN003694, Talazoparib, Pembrolizumab, Sacituzumab Govitecan-hziy, Datopotamab Deruxtecan (Dato-DXd), and others.

Stay ahead with the most recent pipeline outlook for Triple Negative Breast Cancer. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Triple Negative Breast Cancer Treatment Drugs

Triple Negative Breast Cancer Overview

Triple Negative Breast Cancer (TNBC) is defined as a tumor where the estrogen and progesterone (ER/PR) are negative, as assessed by immunohistochemistry (IHC), and there is a lack of overexpression of HER2, as assessed by immunohistochemistry (IHC), or the absence of its gene amplification, as assessed by fluorescence in situ hybridization technique. The epidemiological risk factor profiles also vary between TNBC (ER-PR-HER2-) and other breast cancers. TNBCs are frequently identified as hyper dense masses without associated calcifications. The majority of TNBCs are histologically classified as high-grade, invasive, ductal carcinomas of no special type with basal-like features. Central necrosis, pushing tumor borders, a conspicuous lymphocytic infiltrate, and fibrosis are common histologic features.

Triple Negative Breast Cancer Emerging Drugs

• Trilaciclib: G1 Therapeutics, Inc.

TofaciTrilaciclib, a transient IV-administered CDK4/6 inhibitor, is a novel therapeutic approach which is given before chemotherapy that temporarily blocks progression through the cell cycle. This provides two potential benefits firstly bone marrow protection and therefore the immune system from damage caused by cytotoxic therapy, and secondly improved long term immune surveillance by upregulating the formation of certain memory T cells. Trilaciclib is being evaluated a number of tumor types and chemotherapy regimens to assess its potential myeloprotection, antitumor efficacy and safety in combination with cytotoxic therapies and other anticancer agents. Currently, the drug is in the Phase III stage of its development for the treatment of Triple Negative Breast Cancer.

• Olaparib: AstraZeneca

Olaparib is an oral PARP inhibitor developed by AstraZeneca, approved for BRCA-mutated triple-negative breast cancer (TNBC). It works by blocking PARP enzymes, preventing DNA repair in cancer cells, leading to cell death, particularly in BRCA1/2-mutant tumors. The OlympiAD trial showed that Olaparib significantly improved progression-free survival (PFS) compared to chemotherapy in metastatic TNBC. It is FDA-approved for germline BRCA-mutated, HER2-negative breast cancer and is being explored in combination with immunotherapy and chemotherapy for broader TNBC treatment. Currently, the drug is in the Phase II/III stage of its development for the treatment of Triple Negative Breast Cancer.

• Patritumab Deruxtecan: Daiichi Sankyo Company/Merck

Patritumab deruxtecan (HER3-DXd) is an investigational HER3-directed antibody–drug conjugate (ADC) developed by Daiichi Sankyo. It comprises a fully human anti-HER3 monoclonal antibody linked to a topoisomerase I inhibitor payload via a tumor-selective cleavable linker. HER3 is frequently overexpressed in triple-negative breast cancer (TNBC), correlating with poorer prognosis. In a phase 1/2 trial, patritumab deruxtecan demonstrated promising clinical activity in patients with HER3-expressing metastatic breast cancer. Currently, the drug is in the Phase II stage of its development for the treatment of Triple Negative Breast Cancer.

• NUV-868: Nuvation Bio Inc.

NUV-868 is an experimental drug being studied alone and in combination with PARP inhibitors for the treatment of advanced solid tumors, including triple-negative breast cancer (TNBC). Nuvation Bio had decided not to initiate a Phase II study of NUV-868 as a monotherapy or in combination with olaparib or enzalutamide in the advanced solid tumor indications that were part of the Phase I and Phase Ib study designs. The Company is evaluating next steps for the NUV-868 program, including further development in combination with approved products for indications in which BD2-selective BET inhibitors may improve outcomes for patients. Currently, the drug is in the Phase I/II stage of its development for the treatment of Triple Negative Breast Cancer.

• TUB-030: Tubulis

TUB-030 is an antibody drug conjugate directed against 5T4, an oncofetal antigen, expressed in a broad range of solid tumor types. It consists of an IgG1 antibody targeting 5T4 connected to the Topoisomerase I inhibitor exatecan through a cleavable linker system based on the company’s proprietary P5 conjugation technology with a homogeneous DAR of 8. P5 conjugation is a novel chemistry for cysteine-selective conjugation that enables ADC generation with unprecedented linker stability and biophysical properties. Currently the drug is in Preclinical stage of its development for the treatment of TNBC.

The Triple Negative Breast Cancer Pipeline report provides insights into

• The report provides detailed insights about companies that are developing therapies for the treatment of Triple Negative Breast Cancer with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Triple Negative Breast Cancer Treatment.
• Triple Negative Breast Cancer Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Triple Negative Breast Cancer Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Triple Negative Breast Cancer market

Explore groundbreaking therapies and clinical trials in the Triple Negative Breast Cancer Pipeline. Access DelveInsight's detailed report now! @ New Triple Negative Breast Cancer Drugs

Triple Negative Breast Cancer Companies

Shanghai Henlius Biotech, Jiangsu HengRui Medicine Co., Ltd., G1 Therapeutics, Inc., Infinity Pharmaceuticals, HiberCell, Inc., Zenith Epigenetics, BioLite, Inc., Abbisko Therapeutics, Phoenix Molecular Designs, OncoTherapy Science, ModernaTX, Inc, and others.

Triple Negative Breast Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intravenous
• Subcutaneous
• Oral
• Intramuscular

Triple Negative Breast Cancer Products have been categorized under various Molecule types such as

• Monoclonal antibody
• Small molecule
• Peptide

Unveil the future of Triple Negative Breast Cancer Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight's expert analysis @ Triple Negative Breast Cancer Market Drivers and Barriers

Scope of the Triple Negative Breast Cancer Pipeline Report

• Coverage- Global
• Triple Negative Breast Cancer Companies- Shanghai Henlius Biotech, Jiangsu HengRui Medicine Co., Ltd., G1 Therapeutics, Inc., Infinity Pharmaceuticals, HiberCell, Inc., Zenith Epigenetics, BioLite, Inc., Abbisko Therapeutics, Phoenix Molecular Designs, OncoTherapy Science, ModernaTX, Inc, and others.
• Triple Negative Breast Cancer Pipeline Therapies- Nanosomal Docetaxel Lipid Suspension (75 mg/m2), Taxotere® (100 mg/m2), B013+Nab-Paclitaxel, ZEN003694, Talazoparib, Pembrolizumab, Sacituzumab Govitecan-hziy, Datopotamab Deruxtecan (Dato-DXd), and others.
• Triple Negative Breast Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Triple Negative Breast Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Get the latest on Triple Negative Breast Cancer Therapies and clinical trials. Download DelveInsight's in-depth pipeline report today! @ Triple Negative Breast Cancer Companies, Key Products and Unmet Needs

Table of Content

1. Introduction
2. Triple Negative Breast Cancer Executive Summary
3. Triple Negative Breast Cancer: Overview
4. Triple Negative Breast Cancer Pipeline Therapeutics
5. Triple Negative Breast Cancer Therapeutic Assessment
6. Triple Negative Breast Cancer – DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. Camrelizumab: Jiangsu HengRui Medicine
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. AK117: Akeso Biopharma
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. PMD-026: Phoenix Molecular Designs
15. Drug profiles in the detailed report…..
16. Inactive Products
17. Triple Negative Breast Cancer Companies
18. Triple Negative Breast Cancer Products
19. Triple Negative Breast Cancer Unmet Needs
20. Triple Negative Breast Cancer Market Drivers and Barriers
21. Triple Negative Breast Cancer Future Perspectives and Conclusion
22. Triple Negative Breast Cancer Analyst Views
23. Triple Negative Breast Cancer Key Companies
24. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/report-store/triple-negative-breast-cancer-tnbc-pipeline-insight